The global demand for Monoclonal Antibodies Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Monoclonal antibodies are identical immunoglobulins, generated from a single B-cell clone. It is an old immunological tool with applications in the fields of biochemistry, immunology, biotechnology, and applied biology. These are produced by the body's immune system in response to antigens such as bacteria, fungi, parasites, viruses, chemicals, and other substances. Scientists produce antibodies in the lab to mimic the action of the immune system to treat diseases with the help of immunotherapy. Monoclonal antibodies are generally administered by injection.
Production of monoclonal antibodies is an old practice in laboratory research. It is widely applied in the field of clinical medicine. Research from the laboratory globally is revealing additional applications in diverse branches of sciences. Growing search for new therapeutics is propelling the growth of the market. The continued interest in antibody product development is driven by the rapid advancement and understanding of disease at a molecular level. MAbs are extremely valuable for understanding basic immunological and molecular research due to their high specificity. MAbs are increasingly used for applications such as research and diagnosis, therapeutic tools in cancer and immunological disorders, and pharmacy, thus generating a great demand in the industry. Currently, MAbs account for one-third of all the new treatments for leukaemia, arthritis, breast cancer, and transplant, their role in disease prediction and detection offers promise. Scientist all over the world is looking for COVID-19 treatment. Ongoing research says that monoclonal antibodies could treat or even prevent COVID-19 and could promise as the next big thing for market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of monoclonal antibodies.
The entire monoclonal antibodies market has been sub-categorized into type, production type, indication, and end user. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Production Type
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Microbial Diseases
- Research Institutes
This section covers regional segmentation which accentuates on current and future demand for monoclonal antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Monoclonal Antibodies Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the monoclonal antibodies market include Roche, Eli Lilly, Genentech, Pfizer, Biogen Idec. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.